Uniqure Stock Rises After William Blair Initiates 'Outperform' Rating

Shares of Uniqure NV (NASDAQ: QURE) rose 2.4% in pre-open trading after investment firm William Blair initiated coverage on the stock with an "Outperform" rating.

Analyst Confidence and Pipeline Progress

The new rating from William Blair adds to a broadly bullish analyst consensus for the gene therapy developer. According to the source, Uniqure now has 11 buy-equivalent ratings, one hold, and no sell recommendations from analysts covering the company.

This positive sentiment is largely centered on the company's clinical pipeline, particularly its investigational gene therapy for Huntington’s disease, AMT-130. In July 2026, Uniqure announced it had reached an alignment with the U.S. Food and Drug Administration (FDA) on an accelerated pathway for a Biologics License Application (BLA).

Stock Performance and Financials

Ad

The potential for an accelerated regulatory review for AMT-130 has been a significant catalyst for Uniqure's stock, which has recovered substantially over the last year. The shares are up approximately 175% from a 52-week low of $8.73, though they remain well below the 52-week high of $71.50.

Uniqure has also taken steps to solidify its financial position. The company maintains a strong cash position and recently amended a loan facility with Hercules Capital to extend its financial runway.

Market Context

Uniqure's stock gain occurred on a day with little momentum in the broader market, with the S&P 500 trading flat, suggesting the move was driven by company-specific news. The gene therapy sector has seen renewed investor interest, with peers like REGENXBIO and Voyager Therapeutics also benefiting from what the source described as improved regulatory clarity.